Table 4.
Local cutaneous reaction to revaccination as a measure of protective efficacy of primary LC16m8 vaccination
| Months after initial inoculation | Patients observed | Local reactiona |
|
|---|---|---|---|
| Take (%) | Non-take (%) | ||
| LC16m8 initial vaccination followed by Lister revaccination | |||
| 1 (1–2) | 3 | 0 | 3 (100) |
| 6 (5–7) | 420 | 92 (21.9) | 328 (78.1) |
| 12 (8–13) | 138 | 26 (18.8) | [112 (81.2)]b |
| Ikeda/Dairen initial vaccination followed by Ikeda/Dairen revaccinationc | |||
| Up to 6 | 70 | 6 (8.6) | 64 (91.4) |
| Up to 12 | 714 | 164 (23.0) | 550 (77.0) |
| Up to 24 | 777 | 178 (22.9) | 599 (77.1) |
| Up to 60 | 2024 | 724 (35.8) | 1300 (64.2) |
a
This set of results were obtained from Numazu, Hyogo Prefecture, Tokyo University Hospital, Sakai University, Kyoto University, and Osaka University.
b
Error in original Japanese source [4] shows 111 (80.5).
c
Research relating to vaccine immunogenicity from fiscal year 1964.